Skip to main content

BIO-TECHNE Corp Q1 FY2027 results

  • TECH · Nasdaq
  • Biotechnology
  • Life Sciences Tools & Services
  • S&P 500
$72.80−0.05%Close 13 Nov 2026

BIO-TECHNE Corp reported revenue of $300 million, up 4.6% from a year earlier, net income of $28.3 million and diluted earnings per share of $0.18 against $0.24 for the first quarter of fiscal 2027 (the three months to 30 Sep 2026).

From its quarterly report, filed 6 Nov 2026. Compiled and checked by AapWire.

Q1 FY2027 against Q1 FY2026

Three months to 30 Sep 2026, against the three months to 30 Sep 2025. Amounts in USD.

BIO-TECHNE Corp Q1 FY2027 results against the year-ago quarter
MeasureQ1 FY2027Q1 FY2026Change
Revenue$299.7M$286.6M+4.6%
Gross profit$196.6M$188.1M+4.5%
Gross margin65.6%65.6%−0.0 pts
Operating income$36.60M$47.66M−23.2%
Operating margin12.2%16.6%−4.4 pts
Net income$28.29M$38.18M−25.9%
Diluted EPS$0.18$0.24−25.0%
Operating cash flow$73.11M$27.59M+165%
Capital expenditure$5.92M$5.36M+10.3%
Free cash flow$67.20M$22.22M+202%

Operating KPIs for the quarter

BIO-TECHNE Corp operating KPIs, Q1 FY2027
KPIQ1 FY2027Change on a year
Product and Services revenue$285.2Mup 1.5%
Consumables revenue$237.3Mup 2.4%
Instruments revenue$25.5Mup 16.8%
Services revenue$22.5Mdown 18.3%
Royalty revenue$14.5Mup 156.7%
Protein Sciences revenue$219.7Mup 8.7%
Diagnostics and Spatial Biology revenue$80.2Mup 0.9%
United States revenue$152.7Mdown 1.7%
EMEA, excluding United Kingdom revenue$73.9Mup 13.5%
China revenue$28.9Mup 16.6%
APAC, excluding Greater China revenue$22.5Mup 17.3%
United Kingdom revenue$13.7Mup 4.0%
Rest of World revenue$8.1Mdown 11.0%

Earlier quarters

BIO-TECHNE Corp results, last eight filed quarters
QuarterPeriod endRevenueChange on a yearDiluted EPS
Q1 FY202730 Sep 2026$299.7M+4.6%$0.18
Q4 FY202630 Jun 2026$321.2M+1.3%$0.35
Q3 FY202631 Mar 2026$311.4M−1.5%$0.32
Q2 FY202631 Dec 2025$295.9M−0.4%$0.24
Q1 FY202630 Sep 2025$286.6M−1.0%$0.24
Q4 FY202530 Jun 2025$317.0M+3.5%−$0.11
Q3 FY202531 Mar 2025$316.2M+4.2%$0.14
Q2 FY202531 Dec 2024$297.0M+9.0%$0.22

More on BIO-TECHNE Corp: financial statements · revenue · earnings per share

TECH's results, as they are filed.

Releases read within minutes, guidance against results, the quarter in its eight-quarter history, and an alert on each new report.